FNP: Thyroid Disorders

The fetus is entirely dependent on maternal thyroxine for central nervous system development until the fetal thyroid begins functioning around 12 to 14 weeks. Treating the mother ensures adequate hormone reaches the developing fetus. Option A is incorrect because hypothyroidism does not cause thyroid storm; thyrotoxicosis does. Option C is incorrect as hyperemesis is typically associated with elevated hCG causing transient hyperthyroidism, not hypothyroidism. Option D is incorrect because maternal levothyroxine does not stimulate the fetal gland; it directly supplies the necessary hormone the fetus cannot yet synthesize.

Levothyroxine has a narrow therapeutic index, meaning small differences in bioavailability between brand-name and generic formulations can cause significant clinical changes. When a patient switches formulations, a TSH evaluation is required in six weeks to ensure therapeutic equivalence. Free T4 is less sensitive than TSH for this purpose. Assuming identical bioavailability is unsafe due to variations in excipients. Empirically increasing the dose is inappropriate without first confirming the TSH level.

This patient presents with subclinical hypothyroidism, which is characterized by a mildly elevated TSH in the presence of a normal free T4. In asymptomatic older adults, particularly those over the age of 80, a mildly elevated TSH is frequently a normal physiologic age-related shift rather than a true pathology. Current guidelines recommend that you monitor thyroid function rather than initiate treatment if the TSH remains less than 10 mIU/L. Starting levothyroxine therapy in this population can be dangerous, potentially precipitating arrhythmias or worsening angina in patients with underlying coronary artery disease. Ordering a radioactive iodine uptake scan is indicated for hyperthyroidism, not hypothyroidism. Referring to endocrinology for immediate further evaluation is unnecessary and not cost-effective for an asymptomatic, mild laboratory abnormality that can be safely monitored in primary care.

Graves' autoimmune hyperthyroidism is the most common cause of hyperthyroidism in young adults, characterized by a suppressed TSH, diffuse non-tender goiter, and systemic hypermetabolic symptoms. Toxic multinodular goiter typically presents with palpable, distinct nodules rather than a smooth, diffuse enlargement. Hashimoto's autoimmune thyroiditis causes hypothyroidism with an elevated TSH. Subacute granulomatous thyroiditis presents with a distinctly tender thyroid gland, often following a viral infection, which is absent in this presentation.

Antithyroid medication management changes during pregnancy to balance teratogenic risks against maternal liver toxicity. While propylthiouracil is preferred in the first trimester to avoid methimazole-induced embryopathy, guidelines recommend transitioning to methimazole at the start of the second trimester (around 14 to 16 weeks gestation). This switch minimizes the mother's exposure to the hepatotoxic effects of propylthiouracil, which can cause fulminant liver failure. Option A is incorrect because continuing propylthiouracil unnecessarily prolongs the risk of severe maternal liver injury. Option B is incorrect because discontinuing therapy in a patient requiring treatment risks maternal thyrotoxicosis and fetal complications. Option D is incorrect because increasing the dose is unwarranted when current labs are stable, and it increases toxicity risks.